What question did this study set out to answer?

This research aims to determine whether the SLCO1B1 c.521 T>C variant affects muscular symptoms and the use of PCSK9 inhibitors in severe hypercholesterolemia patients.

April 1, 2026Open Access

The SLCO1B1 c.521 T>C variant (rs4149056) is not associated with muscular symptoms or PCSK9-inhibitor prescription in patients with severe hypercholesterolemia and contemporary lipid lowering therapy

Key Points

This research aims to determine whether the SLCO1B1 c.521 T>C variant affects muscular symptoms and the use of PCSK9 inhibitors in severe hypercholesterolemia patients.
Analyzed patients with severe hypercholesterolemia on contemporary statin therapy.
Assessed the prevalence of muscular symptoms and statin prescription patterns.
Investigated the correlation between SLCO1B1 c.521 T>C variant and clinical outcomes.
No association found between SLCO1B1 c.521 T>C variant and statin-associated muscular symptoms (SAMS).
Statin use was not reduced in patients with the variant.
The prescription of PCSK9 inhibitors was not increased among those carrying the variant.

Abstract

In patients with severe hypercholesterolemia on contemporary statin therapy, the SLCO1B1 c.521 T > C variant was not associated with SAMS, reduced statin use, or increased prescription of PCSK9 inhibitors. The SLCO1B1 c.521 T > C variant appears to have no clear clinical relevance, but testing for it may potentially be harmful, as fear of side effects could result in statin undertreatment.

Ask AI

Helpful

Bookmark

View Full Paper